Back to News
CSL Behring joins IQ Consortium
June 7, 2022
The IQ Consortium is excited to welcome CSL Behring to its membership. CSL Behring is a leading global biotech company driven by its promise to save and improve lives by manufacturing plasma-derived and recombinant therapeutic products for serious and rare diseases.
CSL Behring will be represented on the IQ Board of Directors by Silpa Nuthalapati and Jason Newman.